<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="100035"><DrugName>hepatitis delta virus-targeted siRNA therapy (LNP technology, hepatitis delta virus infection), Arbutus Biopharma</DrugName><DrugSynonyms><Name><Value>hepatitis delta virus-targeted siRNA therapy (LNP technology, hepatitis delta virus infection), Arbutus Biopharma</Value></Name></DrugSynonyms><CompanyOriginator id="1032153">Arbutus Biopharma Corp</CompanyOriginator><CompaniesSecondary><Company id="1032153">Arbutus Biopharma Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1032153" type="Company"><TargetEntity id="4295861697" type="organizationId">Arbutus Biopharma Corp (Pre-Merger)</TargetEntity></SourceEntity><SourceEntity id="362" type="ciIndication"><TargetEntity id="10019762" type="MEDDRA"/><TargetEntity id="D019701" type="MeSH"/><TargetEntity id="-472897966" type="omicsDisease"/><TargetEntity id="431" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="362">Hepatitis D virus infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="991">Antiviral</Action><Action id="26035">siRNA agent</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="103">Oligonucleotide</Technology><Technology id="1668">Nanoparticle formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="349">Lipid</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2017-04-06T09:11:39.000Z</LastModificationDate><ChangeDateLast>2017-04-06T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-28T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1032153" linkType="Company"&gt;Arbutus Biopharma&lt;/ulink&gt; is investigating hepatitis delta virus (HDV)-targeted siRNA therapy delivered through the lipid nanoparticle (LNP) platform, for the potential treatment of HDV infection. In November 2015, preclinical data were presented [&lt;ulink linkID="1712994" linkType="Reference"&gt;1712994&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2015, preclinical data were presented at AASLD's Liver Meeting 2015 in San Francisco, CA. In Huh7-D12 cells treated with a single dose of HDAg targeting siRNA-LNP (20 ng/ml, 1.5 nM), there was an immediate and dose-dependent reduction of HDV positive-strand RNA and HDAg protein observed at 24 h and cytoplasmic HDV RNA were more susceptible. Overall, long-lasting duration of activity was exhibited by HDAg mRNA targeting siRNA which rapidly inhibited HDV RNA and proteins [&lt;ulink linkID="1712994" linkType="Reference"&gt;1712994&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1032153">Arbutus Biopharma Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="362">Hepatitis D virus infection</Indication><StatusDate>2017-04-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1032153">Arbutus Biopharma Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="362">Hepatitis D virus infection</Indication><StatusDate>2015-11-17T00:00:00.000Z</StatusDate><Source id="1712994" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="3445005" number="WO-2016183366" title="Compositions and methods for silencing expression of hepatitis D virus RNA"/><PatentFamily id="3471991" number="WO-2016197132" title="Treating hepatitis B virus infection using CRISPR"/><PatentFamily id="4313611" number="WO-2018232330" title="Therapeutic compositions and methods for treating hepatitis B"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arbutus Biopharma Corp" id="1032153"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>